Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12356099 | 0.83 | PPARG (0.44) | POLBHTTALDH1A1 | |
| SCHEMBL15118484 | 0.79 | ALDH1A1 (0.45) | POLBHTTALDH1A1 | |
| SCHEMBL12356100 | 0.78 | LOXL2 (0.50) | LMNAPOLBALDH1A1KCNH2GAA | |
| SCHEMBL9682915 | 0.78 | MEN1 (0.46) | MEN1KMT2ALMNAPOLBHTT | |
| SCHEMBL1695076 | 0.74 | SMN1; SMN2 (0.66) | MEN1KMT2ALMNAHTTNPC1 | |
| SCHEMBL16722430 | 0.72 | MMP2 (0.48) | MEN1KMT2ALMNAPOLBNPC1 | |
| SCHEMBL4801300 | 0.72 | ALDH1A1 (0.60) | MEN1KMT2ALMNANPC1RAB9A | |
| SCHEMBL1521016 | 0.71 | PTPRF (0.57) | MEN1KMT2ASMN1; SMN2GAACA2 | |
| SCHEMBL16061774 | 0.69 | MEN1 (0.45) | MEN1KMT2ALMNAPOLBNPC1 | |
| SCHEMBL3091161 | 0.69 | TSHR (0.53) | MEN1KMT2ALMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143229-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| US-11260136-B2 | Radio-pharmaceutical complexes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-03-01 | — | — | US | disclosed |
| US-20190298865-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-03 | — | — | US | disclosed |
| EP-3468619-A1 | RADIO-PHARMACEUTICAL COMPLEXES | Bayer Pharma Aktiengesellschaft (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20190091354-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-28 | — | — | US | disclosed |
| EP-3432936-A1 | RADIO-PHARMACEUTICAL COMPLEXES | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017211809-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | WO | disclosed |
| US-20170340759-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2017-11-30 | — | — | US | disclosed |
| EP-3233137-A1 | RADIO-PHARMACEUTICAL COMPLEXES | Bayer AS (NO) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017162555-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016096843-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143229-A1 | RADIO-PHARMACEUTICAL COMPLEXES | EGFR, MET, ERBB2 | TMEM97 605/4885SIGMAR1 1001/4885MEN1 262/4885 |
| US-11260136-B2 | Radio-pharmaceutical complexes | EGFR, MET, ERBB2 | TMEM97 669/4885SIGMAR1 1145/4885MEN1 244/4885 |
| US-20170340759-A1 | RADIO-PHARMACEUTICAL COMPLEXES | PTMS, THOP1, PHPT1 | TMEM97 1287/4885SIGMAR1 1516/4885MEN1 39/4885 |
| US-20190091354-A1 | RADIO-PHARMACEUTICAL COMPLEXES | EGFR, MET, ERBB2 | TMEM97 657/4885SIGMAR1 1098/4885MEN1 257/4885 |
| US-20190298865-A1 | RADIO-PHARMACEUTICAL COMPLEXES | FAP, PHPT1, DNPEP | TMEM97 2590/4885SIGMAR1 4148/4885MEN1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.